Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: A systematic review and meta-analysis

Figures & data

Figure 1. Preferred reporting items for systematic reviews and meta-analysis flow diagram – study selection and exclusion.

Table 1. Characteristics of the included randomized controlled trials

Table 2. Summary of the efficacy and safety outcomes of the included studies

Figure 2. Meta-analysis of progression-free survival (PFS) for targeted agents used as monotherapy or combined therapy in patients with relapsed or refractory MM.

Figure 3. Meta-analysis of overall survival (OS) for targeted agents used as monotherapy or combined therapy in patients with relapsed or refractory MM.

Figure 4. Meta-analysis of any adverse events (AEs) for targeted agents used as monotherapy or combined therapy in patients with relapsed or refractory MM.

Figure 5. Meta-analysis of grade 3/4 AEs for targeted agents used as monotherapy or combined therapy in patients with relapsed or refractory MM.

Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892–901.

 PubMed Web of Science ®Google Scholar

White D, Kassim A, Bhaskar B, Yi J, Wamstad K, Paton VE. Results from AMBER, a randomised phase II of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer 2012;119:339–47.

 PubMed Web of Science ®Google Scholar

Chiou TJ, Wang TH, Chao TY, Lin SF, Tang JL, Chen TY, et al. Randomized phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma. Cancer Investig. 2007;25:140–7.

 PubMed Web of Science ®Google Scholar

GLOBOCAN 2008 v1.2. [Internet]. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer, 2010 [cited 2013 Sep. 03]. Available from: http://globocan.iarc.fr.Globocan/.

 Google Scholar

ClinicalTrials.gov [Internet]. MTD, safety, and efficacy of pomalidomide (CC-4047) alone or with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (NCT00833833). 2013 September 02 [cited 2013 Sep 3]. Available from: http://www.clinicaltrials.gov/show/NCT00833833/.

 Google Scholar